NCT00273390已完成不适用
The Use of Remicade (Infliximab) in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
研究概览
简要总结
This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 9 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The study group will include patients suffering from treatment-resistant vision-threatening uveitis who attend the Uveitis Clinic at Casey Eye Institute.
- •We plan to enroll 32 patients.
排除标准
- •Patients with ocular or systemic infection.
- •Patients with the subtype of uveitis termed pars planitis who have MRI scan evidence of demyelination. There is a theoretical risk of adverse outcome of TNF-alpha inhibition on the clinical course of multiple sclerosis. Patients who suffer from pars planitis are at increased risk of developing multiple sclerosis.
- •Children under the age of
- •Patients with known sensitivity to mouse proteins. Remicade is a chimeric protein with human and murine components.
- •Patients with history of cancer (exception- skin cancers which are curatively resected), organ transplantation (exception- cornea), recent drug or alcohol addiction, or inability to keep appointments.
- •Patients with other serious systemic diseases that could interfere with participation in the study.
- •It is specifically noted that pregnant women and nursing mothers will be excluded from this study.
研究者
相似试验
已完成
3 期
A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid ArthritisRheumatoid ArthritisNCT00236028Centocor, Inc.607
撤回
2 期
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)Toxic Epidermal NecrolysisNCT00372723Loyola University
已完成
3 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid ArthritisRheumatoid Arthritis, JuvenileNCT00036374Centocor, Inc.123
已完成
不适用
Remicade in the Treatment of Patients With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT01850121Göteborg University19
已完成
不适用
Post Marketing Surveillance of RemicadeCrohn's DiseaseAnkylosing SpondylitisNCT00724529Janssen Korea, Ltd., Korea938